DBV Technologies traded at $2.39 this Friday July 1st, decreasing $0.16 or 6.27 percent since the previous trading session. Looking back, over the last four weeks, DBV Technologies lost 52.23 percent. Over the last 12 months, its price fell by 58.00 percent. Looking ahead, we forecast DBV Technologies to be priced at 2.41 by the end of this quarter and at 2.16 in one year, according to Trading Economics global macro models projections and analysts expectations.

Stock Price
2.39
Daily Change
-6.27%
Yearly
-58.00%

Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Peers Price Day Year
Acadia Pharmaceuticals 14.37 0.28 1.99% -40.86%
Alnylam Pharmaceuticals 148.25 2.40 1.65% -13.52%
Amarin 1.44 -0.05 -3.36% -67.20%
BioCryst Pharmaceuticals 10.84 0.26 2.46% -34.22%
BioMarin Pharmaceutical 84.98 2.11 2.55% -0.57%
DBV Technologies 2.39 -0.16 -6.27% -58.00%
Esperion Therapeutics 6.45 0.09 1.42% -68.52%
Galectin Therapeutics 1.31 0 0% -58.68%
Halozyme Therapeutics 44.48 0.48 1.09% -4.18%
Intercept Pharmaceuticals 14.13 0.32 2.32% -29.31%
Incyte Corp 77.67 1.70 2.24% -7.07%
Insmed 20.89 1.17 5.93% -26.70%
Ionis Pharmaceuticals 38.06 1.04 2.81% -4.66%
Neurocrine Biosciences 99.25 1.77 1.82% 0.65%
PTC Therapeutics 41.85 1.79 4.47% -2.88%
Ultragenyx Pharmaceutical 62.65 2.99 5.01% -33.50%
Sarepta Therapeutics 75.71 0.75 1.00% 0.62%
United Therapeutics 238.00 2.36 1.00% 29.12%

Indexes Price Day Year
USND 11128 99.11 0.90% -23.99%

DBV Technologies
DBV Technologies SA is a France-based clinical-stage biopharmaceutical company focused on changing the field of immunotherapy by developing a technology platform called Vaskin. The Company's therapeutic approach is based on epicutaneous immunotherapy, or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin. It dedicates its technology to treat patients, including infants and children, suffering from severe food allergies, for whom safety is paramount, since the introduction of the offending allergen into their bloodstream can cause severe or life-threatening allergic reactions, such as anaphylactic shock. The Company's product portfolio for allergy treatments consists of Viaskin Peanut, Viaskin Milk and Viaskin Egg. The Company operates one subsidiary DBV Technologies Inc. in the United States.